A randomized, single-dose, pharmacokinetic equivalence study comparing MB02 (proposed biosimilar) and reference bevacizumab in healthy Japanese male volunteers

PURPOSE: MB02 is a biosimilar to bevacizumab that has demonstrated similar physicochemical and functional properties in in vitro studies to the reference bevacizumab (Avastin(®)). This study aims to assess the pharmacokinetic (PK) similarity of MB02 to the reference bevacizumab in Japanese populatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Eto, Takashi, Karasuyama, Yuji, González, Verónica, Del Campo García, Ana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8367884/
https://www.ncbi.nlm.nih.gov/pubmed/34269848
http://dx.doi.org/10.1007/s00280-021-04324-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8367884/
https://www.ncbi.nlm.nih.gov/pubmed/34269848
http://dx.doi.org/10.1007/s00280-021-04324-z

Ejemplares similares